2.Éû¿ÕÇò¼Á¥¸¥¹¥È¥í¥Õ¥£¡¼¤Î¸¦µæ¤Î¸½¾õ¤È¸¦µæÈɤμèÁÈ

B¡¥ALD¤È»éËûÀÂå¼Õ°Û¾ï

ALD¤Ë¤ª¤±¤ë¶ËĹº¿»éËûÀ¤ÎÃßÀÑ

ALD¤ÏÂçǾ¤Ë¤ª¤±¤ë¹­ÈϰϤÎæ¿ñ¤ÈÉû¿ÕÉÔÁ´¤òÆÃħ¤È¤¹¤ë¼À´µ¤Ç¤¹¤¬¡¢·ìÃæ¤ä¼ï¡¹¤ÎÁÈ¿¥¡ÊÆäËǾÇò¼Á¤äÉû¿ÕÈé¼Á¡Ë¤Ë¤ª¤¤¤Æ¡¢ÃºÁÇ¿ô22°Ê¾å¤Î¶ËĹº¿»éËûÀ¤¬ÃßÀѤ¹¤ëÆÃħ¤ò¤â¤Ã¤Æ¤¤¤Þ¤¹¡£ÃºÁÇ¿ô24¤Ê¤é¤Ó¤Ë26¤ÎË°Ï»éËûÀ¤¬Àµ¾ï¤ÎÌó2¡Á10ÇÜÁý²Ã¤·¤Æ¤ª¤ê¡¢À¸²½³ØŪ¿ÇÃǤËÍøÍѤµ¤ì¤Æ¤¤¤Þ¤¹¡£¤³¤ì¤é¤Î¶ËĹº¿»éËûÀ¤Ï¡¢Ç¾Çò¼Á¤Ç¤Ï¼ç¤È¤·¤Æ¥³¥ì¥¹¥Æ¥í¡¼¥ë¥¨¥¹¥Æ¥ë¡¢Åü»é¼Á¡¢¥¹¥Õ¥£¥ó¥´¥ß¥¨¥ê¥ó¡¢Éû¿ÕÈé¼Á¤Ç¤Ï¥³¥ì¥¹¥Æ¥í¡¼¥ë¥¨¥¹¥Æ¥ë¤È¤·¤Æ¸ºß¤·¤Æ¤¤¤Þ¤¹¡£¶ËĹº¿»éËûÀ¤ÏÁªÂòŪ¤Ë¥Ú¥ë¥ª¥­¥·¥½¡¼¥à¤Ç¦Â»À²½¤µ¤ì¤ë¤³¤È¡¢ALD´µ¼ÔÀþ°Ý²êºÙ˦¤Ç¤Ï¥Ú¥ë¥ª¥­¥·¥½¡¼¥à¤Ë¶Éºß¤¹¤ë¶ËĹº¿»éËûÀCoA¹çÀ®¹ÚÁÇ¡ÊVLCS¡Ë³èÀ­¤¬Äã²¼¤·¤Æ¤¤¤ë¤³¤È¤è¤ê¡¢Åö½éALD¤Ï¡¢VLCS·ç»¾É¤Ç¤Ï¤Ê¤¤¤«¤È¿äÄꤵ¤ì¤Æ¤¤¤Þ¤·¤¿¡£¤·¤«¤·¤Ê¤¬¤éALD¤ÎÉ°ø°äÅÁ»Ò¡ÊALD, ÊÌ̾ABCD1¡Ë¤¬Æ±Äꤵ¤ì¡¢°äÅÁ»Ò¤¬¥³¡¼¥É¤¹¤ë¥¿¥ó¥Ñ¥¯¼Á¡ÊALDP, ÊÌ̾ABCD1¡Ë¤Ï¡¢ATP·ë¹ç¥«¥»¥Ã¥È¡ÊABC¡Ë¥¿¥ó¥Ñ¥¯¼Á¥Õ¥¡¥ß¥ê¡¼¤Ë°¤¹¤ë¥Ú¥ë¥ª¥­¥·¥½¡¼¥àË쥿¥ó¥Ñ¥¯¼Á¤Ç¤¢¤ë¤³¤È¤¬ÌÀ¤é¤«¤Ë¤Ê¤ê¤Þ¤·¤¿¡£ABC¥¿¥ó¥Ñ¥¯¼Á¤ÏATP²Ã¿åʬ²ò¤Î¥¨¥Í¥ë¥®¡¼¤òÍøÍѤ·¡¢À¸ÂÎËì¤ò²ð¤·¤Æ»é¼Á¡¢Åü¡¢¥Ý¥ê¥Ú¥×¥Á¥É¤Ê¤É¤òÍ¢Á÷¤·¤Æ¤¤¤Þ¤¹¡£¤è¤Ã¤ÆALD¤Ï¡¢ALDP¤Î°Û¾ï¤Ë´ð¤Å¤¯¥Ú¥ë¥ª¥­¥·¥½¡¼¥à¤Ç¤Î¶ËĹº¿»éËûÀ¦Â»À²½¤ÎÄã²¼¤¬¸¶°ø¤È¤Ê¤ê¡¢ÃßÀѤ·¤¿¶ËĹº¿»éËûÀ¤¬ºÙ˦¾ã³²¤ò°ú¤­µ¯¤³¤¹¤³¤È¤Ë¤è¤êȯ¾É¤¹¤ë¤Î¤Ç¤Ï¤Ê¤¤¤«¤È¿äÄꤵ¤ì¤Æ¤¤¤Þ¤¹¡£

ºÙ˦Æâ¤Ë¤ª¤±¤ë¶ËĹº¿»éËûÀÂå¼Õ

¶ËĹº¿»éËûÀ¤Ï¿©±Â¤«¤éµÛ¼ý¤µ¤ì¤ë¤È¤È¤â¤Ë¡¢ÃºÁÇ¿ô16¤Î¥Ñ¥ë¥ß¥Á¥ó»À¤Ê¤É¤«¤é¤âÀ¸¹çÀ®¤µ¤ì¤Þ¤¹¡£ºÙ˦Æâ¤Î¶ËĹº¿»éËûÀ¤ÏCoA²½¸å¡¢¥ê¥ó»é¼Á¡¢Åü»é¼Á¡¢¥³¥ì¥¹¥Æ¥í¡¼¥ë¥¨¥¹¥Æ¥ë¤Ê¤É¤Î¹çÀ®¤ËÍøÍѤµ¤ì¤ë¤È¤È¤â¤Ë¡¢¥Ú¥ë¥ª¥­¥·¥½¡¼¥à¤Ç¦Â»À²½¤ò¼õ¤±¤Æʬ²ò¤µ¤ì¤Þ¤¹¡Ê¿Þ£±¡Ë¡£¥Ú¥ë¥ª¥­¥·¥½¡¼¥àËì¾å¤ÎABC¥¿¥ó¥Ñ¥¯¼ÁALDP¤Ï¡¢¶ËĹº¿»éËûÀCoA¤ä¶ËĹº¿»éËûÀ¤ò¸úΨ¤è¤¯¥Ú¥ë¥ª¥­¥·¥½¡¼¥à¤Ë¼è¹þ¤à¤¿¤á¤ËɬÍפȹͤ¨¤é¤ì¤Æ¤¤¤Þ¤¹¡£¤è¤Ã¤Æ¤½¤Î·ç»¤è¤ê¡¢¥Ú¥ë¥ª¥­¥·¥½¡¼¥à¤Ë¤ª¤±¤ë¶ËĹº¿»éËûÀ¦Â»À²½¤ÎÄã²¼¤¬À¸¤¸¤ë¤È¿äÄꤵ¤ì¤Þ¤¹¡£

¶ËĹº¿»éËûÀÃßÀѤÈÉÂÂ֤δØÏ¢À­

úÁǺ¿24¡¢26¤Î˰϶ËĹº¿»éËûÀ¤Ï¡¢Á¿åÀ­¤¬¹â¤¯Ä¾Àþ¾å¤Î¹½Â¤¤ò¤È¤ë¤Î¤Ç¡¢À¸ÂÎËì¤ò¹½À®¤¹¤ë¥ê¥ó»é¼Á¤äÅü»é¼Á¤Ë¼è¹þ¤Þ¤ì¤¿¾ì¹ç¡¢À¸ÂÎËì¤ÎήưÀ­¤äË칽¤¤ËÊѲ½¤ò¤â¤¿¤é¤·¤Þ¤¹¡£¤½¤Î·ë²Ì¡¢À¸ÂÎËì¤ò²ð¤·¤¿¼ï¡¹¤Î¥·¥°¥Ê¥ëÅÁã¤Ë¾ã³²¤¬À¸¤¸¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤Þ¤¹¡£°ìÊý¡¢ALDǾÉÂÊÑÉô¤Ç¤Ï¥ß¥¨¥ê¥ó¤ÎÊø²õ¤È¤È¤â¤Ë±ê¾ÉÀ­¥µ¥¤¥È¥«¥¤¥ó¤Ç¤¢¤ëTNF¦Á¤Ê¤É¤ÎÁý²Ã¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£¸½ºß¡¢¶ËĹº¿»éËûÀÃßÀѤÈæ¿ñ¤Î´Ø·¸¤ÏÉÔÌÀ¤Ç¤¹¤¬¡¢ALDP¤Îµ¡Ç½¾ã³²¤Ë¤è¤ê¶ËĹº¿»éËûÀ¤¬ÃßÀѤ¹¤ë¤È¡¢¥ß¥¯¥í¥°¥ê¥¢¤ä¥¢¥¹¥È¥í¥µ¥¤¥È¤¬³èÀ­²½¤µ¤ì¡¢TNF¦Á¤Ê¤É¤ÎʬÈ礬Áý²Ã¤·¡¢¥ß¥¨¥ê¥ó·ÁÀ®¤Ë´ØÍ¿¤¹¤ë¥ª¥ê¥´¥Ç¥ó¥É¥í¥µ¥¤¥È¤Î¥¢¥Ý¥È¡¼¥·¥¹¤ò¤â¤¿¤é¤¹²ÄǽÀ­¤¬»ØŦ¤µ¤ì¤Æ¤¤¤Þ¤¹¡£¤Þ¤¿¶ËĹº¿»éËûÀ¦Â»À²½¤ÎÄã²¼¤Ï¡¢»é¼ÁÂå¼Õ¤ÈÌ©Àܤ˴ؤï¤ëž¼Ì°ø»ÒPPAR¦Ä¤òÄã²¼¤µ¤»¡¢¥ª¥ê¥´¥Ç¥ó¥É¥í¥µ¥¤¥È¤Îµ¡Ç½¾ã³²¤ò¤â¤¿¤é¤¹²ÄǽÀ­¤â»ØŦ¤µ¤ì¤Æ¤¤¤Þ¤¹¡Ê¿Þ£²¡Ë¡£

¼£ÎÅÌô¤Î²ÄǽÀ­

Lorenzo's oil¡Ê¥ª¥ì¥¤¥ó»À¡§¥¨¥ë¥«»À¡á£´¡§£±¤Îñ²ÁÉÔË°Ï¥ȥꥢ¥·¥ë¥°¥ê¥»¥í¡¼¥ë¡Ë¤òÍѤ¤¤¿¿©±ÂÎÅË¡¤Ë¤è¤ê·ìÃæ¤Î¶ËĹº¿»éËûÀ¤òÄã²¼¤µ¤»¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¤¬¡¢¼£ÎŸú²Ì¤Ï´üÂԤǤ­¤Ê¤¤¤è¤¦¤Ç¤¹¡£ºÇ¶á¥³¥ì¥¹¥Æ¥í¡¼¥ëÀ¸¹çÀ®¤ÎΧ®¹ÚÁǤǤ¢¤ëHMG-CoA´Ô¸µ¹ÚÁǤÎÁ˳²ºÞ¤Ç¤¢¤ë¥í¥Ð¥¹¥¿¥Á¥ó¤¬¡¢ALD´µ¼Ô¤ÎÀþ°Ý²êºÙ˦¤ä·ìÞùÃæ¤Î¶ËĹº¿»éËûÀ¤òÄã²¼¤µ¤»¤ë¤È¤ÎÊó¹ð¤¬¤¢¤ê¤Þ¤·¤¿¡£¤·¤«¤·¤Ê¤¬¤é¡¢¼£ÎÅÌô¤È¤·¤Æ¤ÎÍ­¸úÀ­¤Ë¤Ä¤¤¤Æ¤ÏÈÝÄêŪ¤Ç¤¹¡£¤Þ¤¿Ç¢ÁÇ¥µ¥¤¥¯¥ë·ç»¾É¤Î´µ¼Ô¤Ë»È¤ï¤ì¤¿4-¥Õ¥§¥Ë¥ë¥Ö¥Á¥ì¡¼¥È¤ä¥Ò¥¹¥È¥ó楢¥»¥Á¥ë²½¹ÚÁÇÁ˳²Ìô¥È¥ê¥³¥¹¥¿¥óA¤ËALD´µ¼ÔÀþ°Ý²êºÙ˦¤Ç¤Î¶ËĹº¿»éËûÀ¦Â»À²½²þÁ±¤È¤½¤Î´ÞÎ̤ÎÄã²¼¤¬Êó¹ð¤µ¤ì¤Þ¤·¤¿¡£»ä¤¿¤Á¤Ï¡¢¿¢ÊªÍ³Íè¥Õ¥é¥Ü¥Î¥¤¥ÉͶƳÂΥХ¤¥«¥ì¥ó¥È¥ê¥á¥Á¥ë¥¨¡¼¥Æ¥ë¤¬¡¢ALD´µ¼ÔÀþ°Ý²êºÙ˦¤Ë¤ª¤±¤ë¶ËĹº¿»éËûÀÂå¼Õ¤ò²þÁ±¤·¡¢ºÙ˦Æâ¤Î¶ËĹº¿»éËûÀ´ÞÎ̤òÄã²¼¤µ¤»¤ë¤³¤È¤ò¸«½Ð¤·¤Þ¤·¤¿¡£¸½ºß¡¢ALDP¥Î¥Ã¥¯¥¢¥¦¥È¥Þ¥¦¥¹¤Ç¤ÎǾÆâ¶ËĹº¿»éËûÀ´ÞÎÌÄã²¼¤Ê¤É¤ò»Øɸ¤Ë¡¢¼£ÎÅÌô¤Î³«È¯¤ò¿Ê¤á¤Æ¤¤¤Þ¤¹¡£
¡Êº£Ãæ¾ïͺ¡¢ÉÙ»³Âç³ØÂç³Ø±¡°å³ØÌô³Ø¸¦µæÉôʬ»ÒºÙ˦µ¡Ç½³Ø¡Ë

ʸ¸¥

  1. ¼éÅIJí»Ö¡¢º£Ãæ¾ïͺ (2002) ¥Ú¥ë¥ª¥­¥·¥½¡¼¥àËìABC¥¿¥ó¥Ñ¥¯¼Á¤ÈÉû¿ÕÇò¼Á¥¸¥¹¥È¥í¥Õ¥£¡¼¡¥À¸²½³Ø 74, 1166-1169
  2. Tanaka AR. Tanabe K, Morita M, Kurisu M, Kashiwayama Y, Matsuo M. Kioka N. Amachi T, Imanaka T, Ueda K (2002) ATP binding/hydrolysis by and phosphorylation of peroxisomal ATP-binding cassette proteins PMP70 (ABCD3) and adrenoleukodystrophy protein (ABCD1). J. Biol. Chem. 277, 40142-40147
  3. Morita M, Takahashi I, Kanai M, Okafuji F, Iwashima M, Hayashi T, Watanabe S, Hamazaki T, Shimozawa N, Suzuki Y, Furuya H, Yamada T, Imanaka T (2005) Baicalein 5,6,7-trimethyl ether, a flavonoid derivative, stimulates fatty acid -oxidation in skin fibroblasts of X-linked adrenoleukodystrophy. FEBS Lett. 579, 409-414
  4. ¼éÅIJí»Ö¡¢º£Ãæ¾ïͺ (2005) »é¼ÁÂå¼Õ°Û¾ï¤È¿À·ÐÊÑÀ®¼À´µ. ¼Â¸³°å³Ø¡ÊÁý ´©¡Ë¡§¥À¥¤¥Ê¥ß¥Ã¥¯¤Ë¿·Å¸³«¤¹¤ë»é¼Á¸¦µæ. 23, 1020-1026
¿Þ1.Metabolism of very long chain fatty acid (VLCFA) ¿Þ2.Dysfunction of ALDP and adrenoleukodystrophy